Topic: bankruptcy

6. Bind Therapeutics

Bind Therapeutics had the dubious honor of being one of only a handful of biotechs to file for bankruptcy last year. After a series of trial failures, dropped deals and major staff cuts, Bind went into Chapter 11, and its assets were sold off to Pfizer for just $40 million.
Boston Harbor

Bankrupt biotech Bind eyes $20M sale to Pfizer

The Robert Langer-backed nanoparticle cancer biotech Bind, after a decade in the business, looks to be at the end of the road after the company said it was seeking an approval for a “stalking horse” bid today from Pfizer.